Anti-CX3CR1 Nanobody: Phase I started

Boehringer began a Phase I trial to evaluate single ascending doses

Read the full 112 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE